RxDoctor Payments Data

Jeffrey Kitch, APRN

Family · Covington, LANPI 1518107275

Payments from drug & device makers

What this record shows

The money is spread across several categories — food and beverage (57.9%), speaking fees and education — rather than concentrated in one kind of arrangement. 38 manufacturers reported payments, led by Bayer at 50.2% of the total. Reporting peaked in 2022 at $7,039 and has fallen 87.0% since, to $917 in 2025. Among family clinicians in LA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$12,671in general payments, 2019–2025

Across 429 payments — averaging $29.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bayer$6K
  • Johnson & Johnson$738
  • Merck$653
  • Pfizer$576
  • Novo Nordisk$530
  • Sanofi-aventis U.S. LLC$429
  • plus $3K from 32 others

What the payments were for

  • Speaking & faculty fees$5,17041%
  • Food & beverage$7,33858%
  • Education$1621%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,671 in reported general payments places this provider in the 95th percentile of 3,610 family providers in Louisiana.

See all family providers in Louisiana

Medicare billing

Part B allowed, 2024
$20,099
Medicare patients
137
Services billed
307

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban297$253,148
XareltoRivaroxaban164$134,568
Repatha SureclickEvolocumab105$92,287
MounjaroTirzepatide56$70,575
JardianceEmpagliflozin58$61,939
OzempicSemaglutide29$32,801
FarxigaDapagliflozin Propanediol34$31,523
EntrestoSacubitril/Valsartan21$24,212
WegovySemaglutide15$23,383
MultaqDronedarone Hcl19$19,881
KerendiaFinerenone11$19,634
MyrbetriqMirabegron29$16,381
Trelegy ElliptaFluticasone/Umeclidin/Vilanter18$15,112
VascepaIcosapent Ethyl20$13,178
NexlizetBempedoic Acid/Ezetimibe12$9,885

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$576$253,148297 claims
Johnson & JohnsonXarelto$738$134,568164 claims
Lilly USA, LLCMounjaro$14$70,57556 claims
Boehringer IngelheimJardiance$146$61,93958 claims
Novo NordiskOzempic, Wegovy$530$56,18444 claims
AstraZenecaFarxiga, Symbicort$86$36,48751 claims
NovartisEntresto$251$24,21221 claims
Sanofi-aventis U.S. LLCMultaq$429$19,88119 claims
BayerKerendia$6,361$19,63411 claims
Astellas Pharma US IncMyrbetriq$102$16,38129 claims
Esperion Therapeutics, Inc.Nexlizet, Nexletol$219$15,20524 claims
GSKTrelegy Ellipta$17$15,11218 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,610 family providers in Louisiana.

Other family in Covington

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →